<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cells from the EBV-associated <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">tumor, Burkitt's</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), are known to be highly inefficient at endogenous processing of class I-restricted CTL <z:chebi fb="0" ids="53000">epitopes</z:chebi> due to a consistent loss of <z:chebi fb="7" ids="16670">peptide</z:chebi> transporters (TAP) and MHC expression </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the potential of CD40 engagement to up-regulate the expression of class I-processing genes and to enhance the immunogenicity of these malignant cells toward EBV-specific CTLs </plain></SENT>
<SENT sid="2" pm="."><plain>Here we show that engagement of CD40 Ag with soluble CD40 ligand (CD40L) up-regulates TAP-1 and HLA class I expression on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>More importantly, analysis of the Ag-processing function, using a recombinant <z:e sem="disease" ids="C0042214" disease_type="Disease or Syndrome" abbrv="">vaccinia</z:e> virus to transiently express the EBV nuclear Ags, revealed that CD40L-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells consistently processed endogenously synthesized <z:mp ids='MP_0001799'>viral</z:mp> Ags for recognition by HLA class I-restricted, virus-specific CTLs </plain></SENT>
<SENT sid="4" pm="."><plain>These findings raise the possibility that CD40L treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells might be exploited in immunotherapeutic protocols </plain></SENT>
</text></document>